Anamorelin (Fumarate)

Anamorelin (RC-1291) Fumarate is an orally active Ghrelin receptor agonist with an EC₅₀ of 0.74 nM. Anamorelin Fumarate can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin Fumarate can be used in the research of anorexia and cancer cachexia^[1][2]. IC50 & Target:K_i: 0.7 nM (Ghrelin receptor)^[1]
EC₅₀: 0.74 nM (Ghrelin receptor)^[1] In Vitro:Anamorelin (0.01 nM-10 μM; 15 min) Fumarate stimulates growth hormone release in a dose-dependent manner in rat pituitary cells, with an EC₅₀ of 1.5 nM^[1]. In Vivo:Anamorelin (3-30 mg/kg; oral administration; 6 days) Fumarate increases food intake and body weight in rats in a dose-dependent manner^[1].
Anamorelin (3.5 mg/kg; oral administration; 1-7 days) Fumarate significantly elevates the levels of growth hormone and insulin-like growth factor-1 in pigs^[1].
Anamorelin (3-30 mg/kg; oral administration; 28 days) Fumarate does not promote tumor growth in a nude mouse model of lung cancer xenografts, but increases the body weight of nude mice^[2].